Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.45 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18360201 | 0.84 | CYP1A2 (0.43) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL1867256 | 0.84 | CTSS (0.44) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL18360422 | 0.83 | CYP1A2 (0.58) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL18360368 | 0.82 | CYP1A2 (0.41) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL21012901 | 0.81 | CTSK (0.49) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL13936599 | 0.80 | CTSK (0.47) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL18360336 | 0.79 | CTSS (0.57) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL18295821 | 0.79 | CA1 (0.45) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL6240594 | 0.77 | CYP1A2 (0.51) | CTSSCTSKCTSLCTSBCYP1A2 | |
| SCHEMBL24815320 | 0.77 | CTSK (0.65) | CTSSCTSKCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919840-B2 | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials | SEIKAGAKU CORPORATION (JP) | 2021-02-16 | — | — | US | disclosed |
| EP-3101064-B1 | DIAMINE CROSSLINKING AGENT, ACIDIC POLYSACCHARIDE CROSSLINKED BODY, AND MEDICAL MATERIAL | SEIKAGAKU KOGYO CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20190345312-A1 | DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS | SEIKAGAKU CORPORATION (JP) | 2019-11-14 | — | — | US | disclosed |
| US-10294195-B2 | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials | SEIKAGAKU CORPORATION (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20170001948-A1 | DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS | SEIKAGAKU CORPORATION (JP) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294195-B2 | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials | SAT1, ACMSD, ADM2 | CTSS 4147/4885CTSK 4211/4885CTSL 4159/4885 |
| US-20170001948-A1 | DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS | SAT1, ACMSD, ADM2 | CTSS 4147/4885CTSK 4211/4885CTSL 4159/4885 |
| US-10919840-B2 | Diamine crosslinking agents, crosslinked acidic polysaccharides and medical materials | SAT1, ACMSD, ADM2 | CTSS 4147/4885CTSK 4211/4885CTSL 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.